Alfa 1 Antitripsina

Records for this ingredient, by country (identity only).

ATC B02AB02 · 2 markets · 25 records

Alfa 1 Antitripsina 2 markets · 25 records Forms
Filters
MarketCN 17ES 8

CN 17 records · 3 shown of 3 Source 国家医保局 医保药品分类与代码数据库 · Data as of 2025-04-04

  • 278 IU per mL / per unit basis not statedinjection赫泰林抑肽酶Manufacturer: 吉林省辉南长龙生化药业股份有限公司、Manufacturer: 辅仁药业集团有限公司、Manufacturer: 马鞍山丰原制药有限公司
  • 56 IU per mL / per unit basis not statedinjection赫泰林抑肽酶Manufacturer: 吉林省辉南长龙生化药业股份有限公司、Manufacturer: 河南辅仁怀庆堂制药有限公司、Manufacturer: 马鞍山丰原制药有限公司
  • 28 IU per mL / per unit basis not statedinjection赫泰林抑肽酶Manufacturer: 吉林省辉南长龙生化药业股份有限公司、Manufacturer: 河南辅仁怀庆堂制药有限公司

ES 8 records · 4 shown of 4 Source CIMA (AEMPS) · Data as of live

  • 4,000 mg per mL / per unit basis not statedinjectionPROLASPLANPROLASTINA、RESPREEZA
  • 5,000 mg per mL / per unit basis not statedinjectionPROLASTINARESPREEZA
  • 1,000 mg per mL / per unit basis not statedinjectionPROLASPLANPROLASTINA
  • 50 mg per mL / per unit basis not statedinjectionRESPREEZA

Some strengths are recorded without a per mL / per unit basis. They are shown as recorded and are not compared with other markets.

The same ingredient can carry completely different brand names in different countries, and the same name can point to a different ingredient. Listed by country — not interchangeable.

Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.

A side-by-side table is offered only when this ingredient has records in many markets; otherwise this list is the whole picture.